Back Back
Cell No. : Cell Name
RCB0820 : HKBML  update : 2024/01/17
CommentHuman cell line derived from malignant lymphoma occurred in brain. Epstein-Barr virus positive.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Ishiwata, Isamu
Originator Ishiwata, I. & Sato, E. & Ishikawa, H.
Year of deposit 1992
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Tissue brain
Disease name Lymphoma
Classification cancer
Year of origin 1991
Lifespan infinite
Morphology lymphocyte-like
Cellosaurus(Expasy) CVCL_8161
deposit info
lot info
Medium Medium List
Culture type Suspension cells
Culture medium HamF12 + 15% FBS
Culture method
Antibiotics Free
Passage method dilution
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) (-)
Virus (HTLV-1) (-)
Virus (EBV) (+)
Isozyme LD, NP
Chromosome mode 36-96(50) : /45(1),46(2),47(5),48(37),49(1),96(1)
STR(human) OK
deposit info
lot info
Reference information Reference 0
User's Publication 15

To topTop

To topTop
User's Publication
21284  Suzuki K, Yamamoto J, Toh K, Miyaoka R.  5‑aminiolevulinic acid induces a radiodynamic effect with enhanced delayed reactive oxygen species production under hypoxic conditions in lymphoma cells: An in vitro study.  Exp Ther Med  2023  26(1):360  PubMed ID: 37324514   DOI: 10.3892/etm.2023.12059
16945  Yano H, Fujiwara Y, Horlad H, Pan C, Kai K, Niino D, Ohsawa K, Higashi M, Nosaka K, Okuno Y, Tamaru JI, Mukasa A, Matsuoka M, Komohara Y.  Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapy  Cancer Sci  2022  113(6):2129-2143  PubMed ID: 35343027   DOI: 10.1111/cas.15349
20208  Takashima Y, Kawaguchi A, Fukai J, Iwadate Y, Kajiwara K, Hondoh H, Yamanaka R.  Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma.  PLoS One  2021  16(6):e0251272  PubMed ID: 34166375   DOI: 10.1371/journal.pone.0251272
9864  Yasuo Takashima, Azusa Hayano, Ryuya Yamanaka  Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells  Clin Cancer Res  2020  26(11):2754-2766  PubMed ID: 32108030   DOI: 10.1158/1078-0432.CCR-18-3851
11997  Muta H, Sugita Y, Furuta T, Shiimura Y, Ohshima K, Nakashima K, Sato K, Morioka M, Abe H, Nozawa T, Fujii Y, Kakita A.  Expression of the ghrelin/growth hormone secretagogue receptor axis and its functional role in promoting tumor growth in primary central nervous system lymphomas.  Neuropathology  2020    PubMed ID: 31925841   DOI: 10.1111/neup.12634
13062  Takashima Y, Hamano M, Fukai J, Iwadate Y, Kajiwara K, Kobayashi T, Hondoh H, Yamanaka R.  GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL.  Sci Rep  2020    PubMed ID: 32439996   DOI: 10.1038/s41598-020-65463-6
13099  Fujimoto K, Shinojima N, Hayashi M, Nakano T, Ichimura K, Mukasa A.  Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.  Neurooncol Adv  2020    PubMed ID: 32793886   DOI: 10.1093/noajnl/vdaa084
11518  Hayano A, Takashima Y, Yamanaka R.  Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.  Int. J. Clin. Oncol.  2019    PubMed ID: 30993483   DOI: 10.1007/s10147-019-01451-9
11849  Mulazzani M, Huber M, Borchard S, Langer S, Angele B, Schuh E, Meinl E, Dreyling M, Birnbaum T, Straube A, Koedel U, von Baumgarten L.  APRIL and BAFF: novel biomarkers for central nervous system lymphoma.  J Hematol Oncol  2019    PubMed ID: 31615554   DOI: 10.1186/s13045-019-0796-4
6897  Takashima Y, Yoshimura T, Kano Y, Hayano A, Hondoh H, Ikenaka K, Yamanaka R.  Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells.  BMC Cancer  2019  19(1):910  PubMed ID: 31510952   DOI: 10.1186/s12885-019-6129-8
11125  Miyasato Y, Takashima Y, Takeya H, Yano H, Hayano A, Nakagawa T, Makino K, Takeya M, Yamanaka R, Komohara Y.  The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma.  J Clin Exp Hematop  2018  58(2):95-101  PubMed ID: 29998979   DOI: 10.3960/jslrt.18001
11858  Shinojima N, Fujimoto K, Makino K, Todaka K, Yamada K, Mikami Y, Oda K, Nakamura K, Jono H, Kuratsu JI, Nakamura H, Yano S, Mukasa A.  Clinical significance of polyglutamylation in primary central nervous system lymphoma.  Acta Neuropathol Commun  2018    PubMed ID: 29475458   DOI: 10.1186/s40478-018-0522-4
10300  Takahashi Y, Sawada T, Akahane T, Kawase Y, Ikeda H, Makino K, Nakamura H, Hide T, Yano S, Hashimoto N, Kamada H.  Monocyte chemoattractant protein 1 expression and proliferation in primary central nervous system lymphoma.  Oncol Lett  2017  14:264-270  PubMed ID: 28693163   DOI: 10.3892/ol.2017.6122
14351  Ma C, Horlad H, Pan C, Yano H, Ohnishi K, Fujiwara Y, Matsuoka M, Lee A, Niidome T, Yamanaka R, Takeya M, Komohara Y.  Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines   J Clin Exp Hematop  2017  57(1):21-25  PubMed ID: 28496056   DOI: 10.3960/jslrt.17006
7310  Mizowaki T, Sasayama T, Tanaka K, Mizukawa K, Takata K, Nakamizo S, Tanaka H, Nagashima H, Nishihara M, Hirose T, Itoh T, Kohmura E.  STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.  J. Neurooncol.  2015  124:165-74  PubMed ID: 26080800   DOI: 10.1007/s11060-015-1843-9

Back Back Return Top Page